• Kancera AB, of Stockholm, Sweden, said its ROR inhibitors showed an effect in a model of human pancreatic cancer. The compounds were superior in efficacy to gemcitabine. The study was done in collaboration with Matthias Lohr, a professor at the Karolinska Institutet in Stockholm. Read More

EDINBURGH, Scotland – A 10-year plan to create an integrated translational medicine hub in the heart of Edinburgh is beginning to bear fruit, with the first spinouts starting to emerge from the research base and take up residence in a new bioincubator, which opens next week. Read More

Shares in NicOx SA surged almost 35 percent last week on news that the company had taken its first concrete step toward becoming a late-stage development and commercial player in opthalmology by entering a cash-and-shares acquisition agreement with Altacor Ltd. that could be worth as much as £19.5 million (US$30.9 million). Read More

Switzerland's Cytos Biotechnology Ltd. stepped away from the ledge of a financial precipice last week and rescued its lead immunodrug candidate CYT003-QbG10 by forging agreements with a syndicate of international investors to raise up to CHF37 million (US$40.6 million) in equity and debt. Read More

LONDON – A novel method of identifying molecules crucial to the survival of cancer cells has pinpointed an enzyme in prostate cancer cells that, when blocked, kills the cells. Read More

LONDON – Spring has arrived on cue for European biotech with the launch of a new €150 million (US$199 million) venture capital fund from Index Ventures – with backing and active involvement from two pharma partners, GlaxoSmithKline plc and Johnson & Johnson – to specialize in investing in early stage companies. Read More